Linda K. Curtiss

Q: What Schools Are Affiliated With Linda K. Curtiss

Linda K. Curtiss is affiliated with the following schools: University of California, Berkeley, University of New South Wales, University of Sydney, University of California, Los Angeles, University of Washington

Linda K. Curtiss's AcademicInfluence.com Rankings

Linda K. Curtiss

Biology

#11898

World Rank

#15331

Historical Rank

Molecular Biology

#1879

World Rank

#1908

Historical Rank

Biochemistry

#1995

World Rank

#2136

Historical Rank

biology Degrees

Download Badge

Biology

Why Is Linda K. Curtiss Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Linda K. Curtiss's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis (2001) (1176)
Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. (2000) (691)
Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. (1990) (628)
A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. (2001) (617)
Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. (1996) (577)
Modulation of atherosclerosis in mice by Toll-like receptor 2. (2005) (561)
A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. (1998) (560)
Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. (1999) (540)
IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. (2004) (453)
Overexpression of Interleukin-10 by Activated T Lymphocytes Inhibits Atherosclerosis in LDL Receptor–Deficient Mice by Altering Lymphocyte and Macrophage Phenotypes (2002) (378)
Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. (1996) (367)
Apolipoprotein E and atherosclerosis. (2000) (263)
Regulated Expression of the Apolipoprotein E/C-I/C-IV/C-II Gene Cluster in Murine and Human Macrophages (2002) (251)
Increased endothelial expression of Toll-like receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events (2008) (229)
Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a): Short-Term and Long-Term Immunologic Responses to Oxidized Low-Density Lipoprotein (2004) (229)
High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. (1999) (225)
Apolipoprotein A-I structural organization in high density lipoproteins isolated from human plasma (2010) (224)
Treatment of severe hypercholesterolemia in apolipoprotein E-deficient mice by bone marrow transplantation. (1995) (213)
HDL particle size is a critical determinant of ABCA1-mediated macrophage cellular cholesterol export. (2015) (212)
Plasma Apolipoproteins AI, AII, B, CI, and E Are Glucosylated in Hyperglycemic Diabetic Subjects (1985) (209)
Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. (2006) (202)
PPARδ regulates multiple proinflammatory pathways to suppress atherosclerosis (2008) (193)
Serum amyloid A (SAA): influence on HDL-mediated cellular cholesterol efflux. (1995) (190)
Regulatory serum lipoproteins: regulation of lymphocyte stimulation by a species of low density lipoprotein. (1976) (173)
Oxidized LDL induces monocytic cell expression of interleukin-8, a chemokine with T-lymphocyte chemotactic activity. (1994) (169)
Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. (1984) (169)
Emerging role of Toll-like receptors in atherosclerosis Published, JLR Papers in Press, November 1, 2008. (2009) (157)
Apolipoprotein E is a biologically active constituent of the normal immunoregulatory lipoprotein, LDL-In. (1986) (153)
What Is So Special About Apolipoprotein AI in Reverse Cholesterol Transport? (2006) (153)
Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. (2012) (151)
Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo (1999) (142)
The Mechanism of the Remodeling of High Density Lipoproteins by Phospholipid Transfer Protein* (2001) (140)
Arteriosclerosis, Thrombosis, and Vascular Biology. (2016) (133)
Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I (2010) (130)
Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. (1994) (127)
A Minimally Lipidated Form of Cell-derived Apolipoprotein E Exhibits Isoform-specific Stimulation of Neurite Outgrowth in the Absence of Exogenous Lipids or Lipoproteins* (1998) (125)
The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase (2007) (122)
Conservation of the Low Density Lipoprotein Receptor‐Binding Domain of Apoprotein B (1986) (111)
Immunochemical heterogeneity of human plasma apolipoprotein B. I. Apolipoprotein B binding of mouse hybridoma antibodies. (1982) (111)
Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in vivo. (1991) (109)
Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions (2012) (105)
Leukocyte Transglutaminase 2 Expression Limits Atherosclerotic Lesion Size (2005) (104)
Thematic review series: The Immune System and Atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis Published, JLR Papers in Press, January 16, 2005. DOI 10.1194/jlr.R400015-JLR200 (2005) (103)
Chemokines and atherosclerosis. (1998) (102)
Lipoprotein lipase increases lipoprotein binding to the artery wall and increases endothelial layer permeability by formation of lipolysis products. (1997) (102)
The conformation of apolipoprotein A-I in high-density lipoproteins is influenced by core lipid composition and particle size: a surface plasmon resonance study. (2000) (101)
New mechanism for foam cell generation in atherosclerotic lesions. (1987) (100)
Abundant expression of apoprotein E by macrophages in human and rabbit atherosclerotic lesions. (1993) (100)
Monocytes can be induced by lipopolysaccharide-triggered T lymphocytes to express functional factor VII/VIIa protease activity (1984) (97)
Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. (1986) (96)
Interaction of plasma lipoproteins with human platelets. (1984) (96)
Characterization of an abnormal species of apolipoprotein B, apolipoprotein B-37, associated with familial hypobetalipoproteinemia. (1987) (94)
Interferon-gamma inhibits macrophage apolipoprotein E production by posttranslational mechanisms. (1993) (94)
Immunoelectron microscopy of low density lipoproteins yields a ribbon and bow model for the conformation of apolipoprotein B on the lipoprotein surface. (1995) (90)
Effect of γ-Irradiation and Bone Marrow Transplantation on Atherosclerosis in LDL Receptor-Deficient Mice (2001) (89)
A single copy of apolipoprotein B-48 is present on the human chylomicron remnant. (1997) (89)
A novel method for generating region-specific monoclonal antibodies to modified proteins. Application to the identification of human glucosylated low density lipoproteins. (1983) (88)
Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. (1981) (86)
Protection against atherosclerosis by estrogen is independent of plasma cholesterol levels in LDL receptor-deficient mice. (1999) (83)
Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. (1994) (82)
Genetic analysis of a kindred with familial hypobetalipoproteinemia. Evidence for two separate gene defects: one associated with an abnormal apolipoprotein B species, apolipoprotein B-37; and a second associated with low plasma concentrations of apolipoprotein B-100. (1987) (78)
Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor‐related protein/α2‐macroglobulin receptor (1993) (77)
Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals. (1984) (76)
Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro: two procoagulant activities are produced by peripheral blood mononuclear cells. (1981) (74)
Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages and foam cells Published, JLR Papers in Press, May 1, 2003. DOI 10.1194/jlr.M200281-JLR200 (2003) (71)
Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis. (1997) (71)
MyD88 Deficiency Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm Formation Independent of Signaling Through Toll-Like Receptors 2 and 4 (2011) (71)
DNA Vaccination Against VEGF Receptor 2 Reduces Atherosclerosis in LDL Receptor–Deficient Mice (2007) (70)
The Hydrophobic Face Orientation of Apolipoprotein A-I Amphipathic Helix Domain 143–164 Regulates Lecithin:Cholesterol Acyltransferase Activation* (1998) (70)
Monoclonal antibody MB19 detects genetic polymorphism in human apolipoprotein B. (1985) (69)
Immunochemical heterogeneity of human plasma apolipoprotein B. II. Expression of apolipoprotein B epitopes on native lipoproteins. (1982) (68)
Cellular differences in lipoprotein lipase-mediated uptake of low density lipoproteins. (1994) (68)
Apoprotein E-rich high density lipoproteins inhibit ovarian androgen synthesis. (1988) (68)
Localization of an apolipoprotein A-I epitope critical for activation of lecithin-cholesterol acyltransferase. (1991) (67)
Translocation of apolipoprotein B across the endoplasmic reticulum is blocked in abetalipoproteinemia. (1996) (66)
ApoA1 reduces free cholesterol accumulation in atherosclerotic lesions of ApoE-deficient mice transplanted with ApoE-expressing macrophages. (1999) (65)
Mimicry of high-density lipoprotein: functional peptide-lipid nanoparticles based on multivalent peptide constructs. (2013) (64)
Parallel expression of the MB19 genetic polymorphism in apoprotein B-100 and apoprotein B-48. Evidence that both apoproteins are products of the same gene. (1986) (64)
THP-1 cells form foam cells in response to coculture with lipoproteins but not platelets. (1991) (64)
Interaction of Lp(a) with Plasminogen Binding Sites on Cells (1995) (63)
Inflammation in Atherosclerosis: Lesion Formation in LDL Receptor–Deficient Mice With Perforin and Lystbeige Mutations (2002) (62)
ApoE in atherosclerosis : a protein with multiple hats. (2000) (62)
Identification of a lymphocyte surface receptor for low density lipoprotein inhibitor, an immunoregulatory species of normal human serum low density lipoprotein. (1978) (61)
Anti-apoprotein B monoclonal antibodies detect human low density lipoprotein polymorphism. (1984) (60)
A linkage between the hemostatic and immune systems embodied in the fibrinolytic release of lymphocyte suppressive peptides. (1985) (58)
Increased Production of Apolipoprotein B-containing Lipoproteins in the Absence of Hyperlipidemia in Transgenic Mice Expressing Cholesterol 7α-Hydroxylase* (2001) (58)
In vivo suppression of the primary immune response by a species of low density serum lipoprotein. (1977) (58)
The NH2-terminal Region of Apolipoprotein B Is Sufficient for Lipoprotein Association with Glycosaminoglycans* (1998) (58)
Atheroprotective Potential of Macrophage-Derived Phospholipid Transfer Protein in Low-Density Lipoprotein Receptor–Deficient Mice Is Overcome by Apolipoprotein AI Overexpression (2006) (58)
Lipoprotein Lipase Association with Lipoproteins Involves Protein-Protein Interaction with Apolipoprotein B (*) (1995) (57)
Subdomain Chimeras of Hepatic Lipase and Lipoprotein Lipase (1998) (57)
An amino-terminal fragment of apolipoprotein B binds to lipoprotein lipase and may facilitate its binding to endothelial cells. (1994) (56)
Mapping apolipoprotein B on the low density lipoprotein surface by immunoelectron microscopy. (1991) (55)
Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I Published, JLR Papers in Press, February 1, 2005. DOI 10.1194/jlr.M400212-JLR200 (2005) (53)
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. (2005) (50)
Apolipoprotein A-II Inhibits High Density Lipoprotein Remodeling and Lipid-poor Apolipoprotein A-I Formation* (2003) (50)
Adiposity, dyslipidemia, and insulin resistance in mice with targeted deletion of phospholipid scramblase 3 (PLSCR3). (2004) (49)
Alteration in Apolipoprotein A-I 22-Mer Repeat Order Results in a Decrease in Lecithin:Cholesterol Acyltransferase Reactivity* (1997) (49)
Immunochemical heterogeneity of human plasma high density lipoproteins. Identification with apolipoprotein A-I- and A-II-specific monoclonal antibodies. (1985) (48)
Reversing atherosclerosis? (2009) (48)
Structural determinants for the interaction of lipopolysaccharide binding protein with purified high density lipoproteins: role of apolipoprotein A-I. (1997) (48)
Atherosclerosis induced by endogenous and exogenous toll-like receptor (TLR)1 or TLR6 agonists[S] (2012) (47)
Structural features of synthetic peptides of apolipoprotein E that bind the LDL receptor. (1995) (47)
Toll-like receptors and atherosclerosis (2006) (47)
Localization of an apolipoprotein A-I epitope critical for lipoprotein-mediated cholesterol efflux from monocytic cells. (1994) (46)
Expression of human apolipoprotein B90 in transgenic mice. Demonstration that apolipoprotein B90 lacks the structural requirements to form lipoprotein. (1994) (45)
Role of leukocyte-specific LDL receptors on plasma lipoprotein cholesterol and atherosclerosis in mice. (1997) (43)
A synthetic peptide mimic of plasma apolipoprotein E that binds the LDL receptor. (1991) (43)
Single Repeat Deletion in ApoA-I Blocks Cholesterol Esterification and Results in Rapid Catabolism of Δ6 and Wild-type ApoA-I in Transgenic Mice* (2000) (41)
Interaction of NADPH oxidase 1 with Toll-like receptor 2 induces migration of smooth muscle cells. (2013) (41)
Elimination of macrophage-specific apolipoprotein E reduces diet-induced atherosclerosis in C57BL/6J male mice. (1999) (40)
International Federation of Clinical Chemistry (IFCC): Scientific Division, Committee on Apolipoproteins; Working Group of Antibody Reagents: Selection and Characterization of Monoclonal Antibodies for Measuring Plasma Levels of Apolipoproteins A-I and B (1990) (40)
Atherosclerosis in Mice Is Not Affected by a Reduction in Tissue Factor Expression (2005) (39)
Effect of gamma-irradiation and bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice. (2001) (39)
An apolipoprotein E synthetic peptide targets to lipoproteins in plasma and mediates both cellular lipoprotein interactions in vitro and acute clearance of cholesterol-rich lipoproteins in vivo. (1998) (38)
Participation of innate and acquired immunity in atherosclerosis (2000) (38)
Evaluation of a monoclonal antibody-based enzyme-linked immunosorbent assay as a candidate reference method for the measurement of apolipoprotein B-100. (1989) (38)
Facilitated replacement of Kupffer cells expressing a paraoxonase-1 transgene is essential for ameliorating atherosclerosis in mice. (2005) (37)
The LPS2 mutation in TRIF is atheroprotective in hyperlipidemic low density lipoprotein receptor knockout mice (2013) (37)
Differential sensitivity of lymphocyte subpopulations to suppression by low density lipoprotein inhibitor, an immunoregulatory human serum low density lipoprotein. (1979) (37)
Quantitation of plasma apolipoprotein A-I using two monoclonal antibodies in an enzyme-linked immunosorbent assay. (1988) (36)
The toll of Toll-like receptors, especially toll-like receptor 2, on murine atherosclerosis. (2007) (36)
Leukocyte CD11b expression is not essential for the development of atherosclerosis in mice. (2000) (36)
Only multimers of a synthetic peptide of human apolipoprotein E are biologically active. (1991) (36)
Localization of two epitopes of apolipoprotein A-I that are exposed on human high density lipoproteins using monoclonal antibodies and synthetic peptides. (1988) (34)
Effect of LDL-In, a normal immunoregulatory human serum low density lipoprotein, on the interaction of macrophages with lymphocytes proliferating in response to mitogen and allogeneic stimulation. (1977) (34)
Altered epitope expression of human interstitial fluid apolipoprotein A-I reduces its ability to activate lecithin cholesterol acyl transferase. (1992) (33)
Is two out of three enough for ABCG1? (2006) (33)
13C NMR evidence that substitution of glutamine for arginine 3500 in familial defective apolipoprotein B-100 disrupts the conformation of the receptor-binding domain. (1991) (33)
Monoclonal antibody detects Ag polymorphism of apolipoprotein B (1986) (33)
Apolipoprotein B allotypes MB19(1) and MB19(2) in subjects with coronary artery disease and hypercholesterolemia. (1987) (33)
Evidence that phospholipids play a key role in pre-beta apoA-I formation and high-density lipoprotein remodeling. (2002) (32)
In vivo efficacy of HDL-like nanolipid particles containing multivalent peptide mimetics of apolipoprotein A-I[S] (2014) (32)
Lipoprotein B37, a naturally occurring lipoprotein containing the amino-terminal portion of apolipoprotein B100, does not bind to the apolipoprotein B,E (low density lipoprotein) receptor. (1987) (31)
Overexpression of human ApoAI transgene provides long-term atheroprotection in LDL receptor-deficient mice. (2006) (31)
Immunoregulatory plasma low density lipoprotein: the biologic activity and receptor-binding specificity is independent of neutral lipids. (1981) (31)
Plasma lipoproteins with bioregulatory properties including the capacity to regulate lymphocyte function and the immune response. (1981) (31)
Reduced cholesterol and triglycerides in mice with a mutation in Mia2, a liver protein that localizes to ER exit sites[S] (2011) (30)
Interaction between ApoB and Hepatic Lipase Mediates the Uptake of ApoB-containing Lipoproteins* (1998) (30)
Ag(c): Recognition by a Monoclonal Antibody (1986) (28)
Deletion of amino acids Glu146-->Arg160 in human apolipoprotein A-I (ApoA-ISeattle) alters lecithin:cholesterol acyltransferase activity and recruitment of cell phospholipid. (1998) (28)
Physiologic concentrations of normal human plasma lipoproteins inhibit the immortalization of peripheral B lymphocytes by the Epstein-Barr virus. (1981) (28)
Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency Published, JLR Papers in Press, October 10, 2007. (2008) (27)
Toll-like receptors in atherosclerosis. (2007) (27)
The biologic activity of the immunoregulatory lipoprotein, LDL-In is independent of its free fatty acid content. (1981) (25)
Apolipoprotein B mediates the capacity of low density lipoprotein to suppress neutrophil stimulation by particulates. (1986) (22)
Lipoproteins accumulate in immune deposits and are modified by lipid peroxidation in passive Heymann nephritis. (1996) (22)
Stoichiometric binding of apolipoprotein B-specific monoclonal antibodies to low density lipoproteins. (1985) (22)
Localization of Coliphage MS2 A-Protein (1974) (20)
Low density lipoprotein inhibits the physical interaction of phlogistic crystals and inflammatory cells. (1986) (20)
An apolipoprotein E synthetic peptide selectively modulates the transcription of the gene for rat ovarian theca and interstitial cell P450 17alpha-hydroxylase, C17-20 lyase. (1998) (20)
Participation of macrophages in atherosclerotic lesion morphology in LDLr−/− mices⃞s⃞ The online version of this article (available at http://www.jlr.org) contains an additional two figures. Published, JLR Papers in Press, June 1, 2004. DOI 10.1194/jlr.M400036-JLR200 (2004) (20)
Isolation of allele-specific, receptor-binding-defective low density lipoproteins from familial defective apolipoprotein B-100 subjects. (1994) (18)
TLR2 in murine atherosclerosis (2008) (18)
Detection of two apolipoprotein B species (apoBc and apoBg) by a monoclonal antibody. (1987) (18)
Effect of long chain polyunsaturated fatty acids in the sn-2 position of phosphatidylcholine on the interaction with recombinant high density lipoprotein apolipoprotein A-I. (1998) (17)
Influence of the immunoregulatory serum lipoprotein LDL-In on the in vivo proliferation and differentiation of antigen-binding and antibody-secreting lymphocytes during a primary immune response. (1980) (17)
Identification of apolipoprotein B100 polymorphisms that affect low-density lipoprotein metabolism: description of a new approach involving monoclonal antibodies and dynamic light scattering. (1995) (17)
Erratum: Differential expression of oxidation-specifi c epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions (J. Lipid Res. (2012) 53 (2773-2790) (2014) (16)
Platelet-enhanced apolipoprotein E production by human macrophages: a possible role in atherosclerosis. (1988) (16)
Definition of a nonlinear conformational epitope for the apolipoprotein B-100-specific monoclonal antibody, MB47. (1994) (16)
Influence of macrophage-derived apolipoprotein E on plasma lipoprotein distribution of apolipoprotein A-I in apolipoprotein E-deficient mice. (1997) (15)
Dietary fish oil-induced decrease in low density lipoprotein binding to fibroblasts is mediated by apolipoprotein E. (1994) (15)
A method for localizing the early products of nonenzymatic glycosylation in fixed tissue. (1989) (14)
Differences in the characteristics of inhibition of lymphocyte stimulation by 25-hydroxycholesterol and by the immunoregulatory serum lipoprotein LDL-In. (1980) (13)
MyD 88 Deficiency Attenuates Angiotensin II-Induced Abdominal Aortic Aneurysm Formation Independent of Signaling Through Toll-Like Receptors 2 and 4 (2011) (13)
Comparison of the Effects of Apo(a) Kringle IV-10 and Plasminogen Kringles on the Interactions of Lipoprotein(a) with Regulatory Molecules (1999) (13)
Interaction of lipoprotein (a) with the extracellular matrix (1998) (12)
Effects of chronic mental stress and atherogenic diet on the immune inflammatory environment in mouse aorta (2011) (12)
Cord blood plasma lipoproteins inhibit mitogen-stimulated lymphocyte proliferation. (1984) (12)
Regulatory roles of T mu and T gamma cells in the collaborative cellular initiation of the extrinsic coagulation pathway by bacterial lipopolysaccharide. (1985) (12)
Activation of the first component of human complement, C1, by monoclonal antibodies directed against different domains of subcomponent C1q. (1986) (12)
Platelet-mediated foam cell formation in atherosclerosis. (1990) (11)
Disruption of tissue-specific fucosyltransferase VII, an enzyme necessary for selectin ligand synthesis, suppresses atherosclerosis in mice. (2009) (11)
THE BIOREGULATORY PROPERTIES OF SERUM LOW DENSITY LIPOPROTEIN INHIBITOR (LDL-IN) ON THE GENERATION OF KILLER T CELLS (1977) (11)
Dissociation of LPL and LDL: effects of lipoproteins and anti-apoB antibodies. (1997) (10)
Selection of monoclonal antibodies for linear epitopes of an apolipoprotein yields antibodies with comparable affinity for lipid-free and lipid-associated apolipoprotein. (1996) (10)
The Immunosuppressive Activity of Plasmic Degradation Products of Human Fibrinogen (1977) (10)
Activation of C1 by monoclonal antibodies directed against C1q. (1985) (9)
Modulation of peripheral blood mononuclear cell cyclic adenosine monophosphate levels by human very low density lipoprotein (1981) (9)
Studying low-density lipoprotein-monoclonal antibody complexes using dynamic laser light scattering and analytical ultracentrifugation. (1999) (8)
Identification and properties of glycated monoclonal IgA that affect the fructosamine assay. (2003) (8)
Monocytes can be induced by lipo poly saccharide stimulated t cells to express factor vii activity (1983) (6)
Application of Monoclonal Antibodies to Issues of Plasma Lipoprotein Structure and Function (1985) (5)
Arteriosclerosis, Thrombosis, and Vascular Biology. (2017) (5)
High-level lipoprotein [a] expression in transgenic mice: Published, JLR Papers in Press, January 16, 2005. DOI 10.1194/jlr.M400467-JLR200evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins (2005) (4)
SUPPRESSION OF THE IN VIVO HUMORAL IMMUNE RESPONSE BY A SPECIES OF NORMAN HUMAN SERUM LOW DENSITY LIPOPROTEIN (1977) (4)
Effect of g-Irradiation and Bone Marrow Transplantation on Atherosclerosis in LDL Receptor–Deficient Mice (2001) (4)
The relative immunodominance of haptenic determinants on a complex hapten phage conjugate. (1975) (3)
Expression of the Lyst(beige) mutation is atheroprotective in chow-fed apolipoprotein E-deficient mice. (2008) (3)
Kinetics of C1 activation by a monoclonal anti-C1q antibody and its (Fab)2 fragments. (1987) (3)
Glycosaminoglycans alter the capacity of low density lipoprotein to bind to monosodium urate crystals. (1990) (3)
International Federation of Clinical Chemistry (IFCC) Scientific Division. Committee on Apolipoproteins, Working Group on Antibody Reagents. Selection and characterization of monoclonal antibodies for measuring plasma levels of apolipoproteins A-I and B. (1990) (3)
[19] Immunochemical isolation and identification of glucosylated apolipoproteins (1986) (2)
Immunochemical isolation and identification of glucosylated apolipoproteins. (1986) (2)
Expression of the Lystbeige mutation is atheroprotective in chow-fed apolipoprotein E-deficient mices⃞s⃞ The online version of this article (available at http://www.jlr.org) contains supplementary data in the form of two figures. Published, JLR Papers in Press, November 2, 2007. (2008) (2)
The use of monoclonal antibodies to detect genetic polymorphism: application to apolipoprotein B. (1985) (2)
Feasibility of an immunoassay for mevalonolactone. (1997) (2)
IS144 The Role of IL-8 and Its Receptor CXCR2 in Atherosclerosis (2000) (1)
4P-0998 Pathophysiologic interrelationship of OxLDL and Lp(a) in human coronary plaque disruption and acute coronary syndromes (2003) (1)
Abstract: 143 ENDOTHELIAL CELL TOLL-LIKE RECEPTOR EXPRESSION AND MACROPHAGE ACCUMULATION ARE INCREASED ONLY IN REGIONS OF DISTURBED BLOOD FLOW IN THE MOUSE AORTA (2009) (1)
4.P.327 Locally available apolipoprotein AI reduces cholesterol accumulation in the atherosclerotic lesion (1997) (1)
Bone marrow-derived HL mitigates bone marrow-derived CETP-mediated decreases in HDL in mice globally deficient in HL and the LDLr (2014) (1)
Influence of triglyceride enrichment on the remodelling of high density lipoproteins by PLTP (2000) (1)
The influence of antigen on a model for analysis of multiple coordinate events associated with the primary immune response. (1979) (1)
A RECEPTOR FOR NORMAL HUMAN SERUM LOW DENSITY LIPOPROTEINS ON PERIPHERAL BLOOD LYMPHOCYTES (1977) (1)
Purification and characterization of coliphage MS2 hapten conjugates. (1973) (1)
Abstract 1356: Endothelial Cell Toll-Like Receptor 2 Expression And Macrophage Number Are Increased At Sites Of Disturbed Blood Flow In The Mouse Aorta (2006) (0)
Monoclonal antibodies specific for apolipoprotein B, which are produced by two hybridomas. (1987) (0)
produced two new hybridoma apolipoprotein B specific monoclonal antibodies (1987) (0)
Abstract: S2-4 OPTICAL ANALYSIS OF TLR FUNCTION IN ATHEROMA (2009) (0)
Congratulations to Dr Elizabeth G. Nabel (2005) (0)
Effect of &ggr;-Irradiation and Bone Marrow Transplantation on Atherosclerosis in LDL Receptor-Deficient Mice (2001) (0)
Monoclonal antibody b 19 detects distinct epitope polymorphism in human apo b (1985) (0)
Identification of the major biological effect of ldl-in mediated immunosuppression of the primary immune response in vivo. Abstr. (1979) (0)
IMMUNOSUPPRESSION BY NEONATAL APOLIPOPROTEIN E (1984) (0)
Lipoprotein regulation of lh-stimulated androgen production by theca-interstitial cells (1984) (0)
Estradiol selectivity inhibits oxidation of HDL (1994) (0)
4.P.378 HDL has anticoagulant cofactor activity for the protein C pathway (1997) (0)
The monoclonal paratopic molecule and is for use in hybridoma-secreting Apolipoprotein AI for the determination of (1987) (0)
Activated Platelets Induce Cholesteryl Ester Accumulation in Monocyte-Derived Macrophages and THP-1 Cells (1990) (0)
TwoNewMonoclonal Antibody-Based Enzyme-Linked Assaysof Apolipoprotein B (1986) (0)
Human Apolipoprotein Bsp cific Hybridoma Antibodies 15215 (2001) (0)
directed against different domains of complement, C1, by monoclonal antibodies Activation of the first component of human (2001) (0)
The monitor foerfarande Foer bestaemning of stabilt glucohemoglobin (1987) (0)
The immunoregulatory plasma lipoprotein, ldl-in, is a set of intermediate density lipoprotein: immunochemical evidence using monoclonal antibodies. Abstr. (1981) (0)
Regulation of Pathways of Lymphocyte Differentiation by the Serum Lipoprotein: LDL-In (1980) (0)
Cholesterol, Apolipoprotein E, and Immune Cell Function (2020) (0)
specific monoclonal antibodies of apolipoprotein B, produced by two new hybridomas. (1987) (0)
Immunochemical method for the determination of stable glycosylated hemoglobin and diagnostic system for use in this method, Sam (1987) (0)
Lipoprotein-Associated Phospholipase A2 and Cardiovascular Risk: State of the Evidence and Future Directions (2005) (0)
Abstract 42: Monocyte Tissue Factor-Dependent Activation of Coagulation in Hypercholesterolemic Mice and Monkeys Is Inhibited by Simvastatin (2012) (0)
of a Lymphocyte Surface Receptor for Low Density Lipoprotein Inhibitor, an Immunoregulatory Species of Normal Human Serum Low (1977) (0)
1SY02-3 Innate immunity in atherosclerosis (2003) (0)
Multivalent Peptide-Mimetics of Apolipoprotein A-I That Modulate HDL Particles to Combat Atherosclerosis (2013) (0)
Immunochemical method for determination of stable glycosylated hemoglobin. (1987) (0)
Abstract 1518: Exacerbated Atherosclerosis in CD36 Null Mice may be due to Decreased Titers of IgM Antibodies that Bind Oxidized Low-Density Lipoproteins (2006) (0)
High Density Lipoprotein-Specific Monoclonal Antibodies (1985) (0)
Analytical method and diagnostic kit for the study of abnormal lipid metabolism (1987) (0)
Generation of region‐specific antibodies to modified proteins (1987) (0)
1P-0267 Role of macrophages in the unique atherosclerotic lesion morphology of LDL receptor-deficiet mice with a Lystbeige mutation (2003) (0)
Monoclonal paratopic molecules, hybridomas producing these molecules and their use in determining the apoli (1987) (0)
2009 George L. Duff Memorial Lecture--The Toll of Toll-Like Receptors on Atherosclerosis (2009) (0)
Novel Agents that Prevent Atherosclerosis: Multivalent Peptide Constructs and Self-Assembling Cyclic DL-α-Peptides (2015) (0)
Method for testing immune glycated hemoglobin stable. (1987) (0)
Polypeptidanaloger of apolipoprotein E, diagnostisk System Science metoder aer industry analoger anvaends. (1992) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Linda K. Curtiss?

Linda K. Curtiss is affiliated with the following schools:

Linda K. Curtiss's Academic­Influence.com Rankings

Why Is Linda K. Curtiss Influential?

Linda K. Curtiss's Published Works

Published Works

What Schools Are Affiliated With Linda K. Curtiss?

Linda K. Curtiss's AcademicInfluence.com Rankings